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Abstract 
There are multiple intrinsic mechanisms for diastolic dysfunction ranging from molecular to structural 
derangements in ventricular myocardium. The molecular mechanisms regulating the progression from normal 
diastolic function to severe dysfunction still remain poorly understood. Recent studies suggest a potentially 
important role of core cardio-enriched transcription factors (TFs) in the control of cardiac diastolic function in 
health and disease through their ability to regulate the expression of target genes involved in the process of 
adaptive and maladaptive cardiac remodeling. The current relevant findings on the role of a variety of such 
TFs (TBX5, GATA-4/6, SRF, MYOCD, NRF2, and PITX2) in cardiac diastolic dysfunction and failure are 
updated, emphasizing their potential as promising targets for novel treatment strategies. In turn, the new 
animal models described here will be key tools in determining the underlying molecular mechanisms of 
disease. Since diastolic dysfunction is regulated by various TFs, which are also involved in cross talk with 
each other, there is a need for more in-depth research from a biomedical perspective in order to establish 
efficient therapeutic strategies. 
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Introduction 
Heart failure with preserved ejection fraction (HFpEF), termed in the past “diastolic HF,” is a 
heterogeneous clinical syndrome of impaired diastolic function with normal or near normal left 
ventricular EF (LVEF ≥ 50 %). Patients with HFpEF have a normal-sized LV, often with signs of 
a mild hypertrophy, with impaired filling, to different degrees, due to abnormal LV relaxation and 
increased LV stiffness. While extra-cardiac pathophysiological conditions, such as hypertension, 
obesity, diabetes mellitus, renal dysfunction, and aging, can contribute to HFpEF development, a 
maladaptive concentric LV remodeling appears to be the main underlying substrate of impaired 
diastolic function in patients (recently reviewed in [1–7]). 
 
Studies of gene expression in human HFpEF settings are limited by the low availability of 
tissue samples from diseased and non-failing control hearts. These limitations with human cardiac 
tissue are overcome, with varying degrees of success, by the use of patient-mimicking animal 
models [8, 9] in which HFpEF is developed as a consequence of spontaneous and experimentally 
induced hypertension or metabolic syndromes (obesity and diabetes). The results of these and 
other cross-sectional studies showed that LV diastolic dysfunction conditions can be associated 
with: (1) fluctuation in cardiac calcium-handling protein levels [10], (2) alterations in proteins, 
which play an important role in maintaining the sarcomeric structure and functionality [11–13], 
and (3) aberrant extracellular matrix protein turnover [14–17]. Although these data reflect some 
underlying expression features in HFpEF settings, the molecular mechanisms regulating the 
progression from normal diastolic function to severe dysfunction and then to HFpEF still remain 
poorly understood. Only a few recent studies point to the cardiomyocyte circadian clock [18] and 
mineralocorticoid receptor signaling [19] as potentially important mediators in triggering and in 
the progression of diastolic dysfunction in mice. 
 
Transcription factors (TFs) are essential players in the control of gene expression by 
influencing RNA polymerase activity in a gene-selective manner. One distinct feature of TFs is 
that they have DNA-binding domains which recognize specific sequences in the promoters or 
enhancers of target genes. The other characteristic feature of their structure is an 
activation/repression domain that interacts with various cofactors, which either promote or impair 
the transactivation of target genes. Normal heart development is orchestrated by a suite of highly 
conserved TFs that includes (among others) TBX5, GATA-4, GATA-6, SRF/MYOCD, NRF2, and 
PITX2 (Fig. 1a). These multifaceted cardio-enriched TFs are responsible for the tight regulation of 
expression of a broad array of myocardial-related genes during heart development, and the 
perturbation of expression and regulation of these TFs disrupts normal heart structure and function 
(recently reviewed in [20, 21]). Of note, these core TFs can physically interact with each other and 
co-occupy the promoters of target genes (Fig. 1b). These TFs are co-expressed in the adult human 
myocardium (Fig. 1c), suggesting that interactions between them could be physiologically relevant 
in heart. 
 
It has become increasingly apparent that fetal cardiac-enriched TFs play critical roles in the 
regulation of expression of many myocardial genes in the adult normal and diseased heart 
(reviewed in [22–24]). Regarding heart disease, there is recent, mounting evidence suggesting a 
causal and specific role of several cardiac-enriched TFs in development and progression of 
HFpEF. In this review, we provide a research status update of the expression and function of the 
fetal cardiac TFs in adult diastolic dysfunction. Targeting TFs could be a promising therapeutic 
approach to modulate gene expression in the HFpEF in a specific fashion. Although TFs have 
traditionally been considered as “undruggable” targets for therapeutics, targeting them, due to 
recent technological advances, is again becoming a realistic therapeutic perspective (recently 





Fig. 1. Schematic overview of cardiac-enriched transcription factors governing diastolic function. a 
DNA-binding and transactivation domains of the human TBX5, GATA-4, GATA-6, SRF, NRF2, and 
PITX2 transcription factors (TFs) are shown [129]. N/C: amino/carboxyl terminus; aa—amino acids. b 
Combinatorial TF interactions. Schematic illustrates TBX5::GATA4 [130], TBX5::GATA-6 [131], 
TBX5::MYOCD [132], GATA-4::GATA-6 [54], SRF::MYOCD [68], SRF::PITX2 [133], 
PIXT2::GATA-4 [134], and PITX2::NRF2 [82] protein–protein interactions that lead to cooperative 
regulation of target gene expression in vitro. cTBX5 [29], GATA-4 [135], SRF [136], MYOCD [137], 
NRF2 [138], and PITX2 [97] are co-expressed in the adult human left ventricle (LV), suggesting that the 
interplay of these TFs in vitro (shown in b) also takes place in vivo (data for GATA-6 equivalent to those 
for GATA-4 are currently lacking). LVTF—left ventricular TF machinery which can be involved in 
molecular regulation of diastolic function 
  
TBX5 transcription factor 
The TBX5 gene belongs to a family of genes that share the so-called T-box DNA-binding 
domain of about 180 amino acid residues (reviewed in [26–28]). TBX5 is expressed in human 
embryonic and adult heart [29] and transcriptionally activates multiple cardiomyocyte lineage-
associated genes encoding, among others, NPPA (natriuretic peptide precursor A or ANP), CX40 
(connexin 40), MYH7 (myosin, heavy chain 7, cardiac muscle, beta), TNNI2 (troponin I type 2 
skeletal), TNNT2 (troponin T type 2 cardiac), and SCN5A (sodium channel, voltage-gated, type V 
alpha subunit) [30, 31]. It should be noted that several splicing variants of TBX5 mRNA have been 
identified in the adult mouse [32] and human heart [33], and the resulting protein isoforms are 
characterized by diverse transcriptional and functional activities. This production of different 
TBX5 isoforms seems to be a mechanism which can play an important role in TBX5 dosage 
regulation. 
 
TBX5 function in the heart appears to be exquisitely sensitive to gene dosage. Both over- and 
under-expression of the TBX5 gene have equally deleterious effects on the heart. In transgenic 
mouse embryos, cardiac TBX5 overexpression results in inhibition of ventricular-specific gene 
expression and impaired ventricular trabeculation [34]. Similarly, in humans, TBX5 
overexpression due to gene duplication leads to cardiac abnormalities [35]. In the mouse, systemic 
TBX5 gene ablation (TBX5
−/−
 mice) causes decreased expression of myocardial genes associated 
with extreme underdevelopment of the heart, whereas heterozygous TBX5
−/+
 mice mimic heart and 
limb abnormalities observed in Holt–Oram (“heart-hand”) syndrome (HOS) in humans [36]. Of 
note, TBX5 was the first T-box gene where loss-of-function mutations (mainly located within the 
highly conserved T-box domain) were found to cause a HOS (recently reviewed in [37]); diastolic 
dysfunction is detected in a cohort of HOS patients [38]. Patients with low diastolic blood pressure 
show substantially increased ventricular–arterial stiffness and a tendency for diastolic dysfunction 
(reviewed in [39]). In this regard, large-scale genome-wide association studies have identified an 
association of TBX5 with diastolic blood pressure [40]. 
 
Mice with heterozygous conditional deletion of TBX5 (TBX5
del/+
 mice) manifested a clear LV 
diastolic dysfunction (attributed to a disturbance of LV isovolumic relaxation) with preserved LV 
systolic function. In addition, a significant correlation was found between decreased TBX5 gene 
expression and increased LV filling pressure [41]. However, the possibility that deterioration of 
LV relaxation is secondary to right heart overloads due to atrial or ventricular septal defects in 
these mice could not be excluded. The latter issue has been addressed by Zhu et al. [38] who 
generated mice (TBX5
Vdel/+
 mice) with haploinsufficiency of TBX5 in only ventricular 
cardiomyocytes. These mice did not have septal or any other defects in cardiac structure, but did 
manifest impaired ventricular relaxation and diastolic dysfunction, whereas the systolic function 
remained normal. In the LV of TBX5
Vdel/+
 mice, the decrease in TBX5 expression was paralleled by 
a comparable reduction in transcript and protein levels of SERCA2a (sarcoplasmic reticulum Ca
2+
 
ATPase) which was found to be a dose-dependent target of TBX5 in cardiomyocytes. This model 
suggests that the molecular pathogenesis of isolated diastolic dysfunction is due to downregulation 
of the TBX5–SERCA2a pathway in ventricular cardiomyocytes that may have implications for 
clinical management. Intriguingly, in this regard, a significant downregulation of cardiac 
SERCA2a levels has been observed in the diabetic (mRen-2)27 rat model of HFpEF [10]. 
GATA-4 and GATA-6 transcription factors 
GATA-binding protein 4 (GATA-4) and GATA-binding protein 6 (GATA-6) are the members 
of the GATA family of zinc finger transcription factors which recognize the GATA motif in the 
promoters of most cardiac muscle-specific genes, especially those that are altered by the 
hypertrophic response (reviewed in [24, 42]). GATA-4 directly regulates expression of MYH6 
(myosin, heavy chain 6, cardiac muscle, alpha), MYL1 (myosin, light chain 1, alkali, skeletal, 
fast), TNNC1 (cardiac troponin C type 1), NPPA (natriuretic peptide precursor A), NPPB 
(natriuretic peptide precursor B), ANKRD1 (cardiac-restricted ankyrin repeat protein 1), SLC8A1 
(solute carrier family 8 sodium/calcium exchanger, member 1), and CDK2 and 4 (cyclin-
dependent kinase 2 and 4) [42–44]. GATA-6 seems to regulate the expression of NPPA, EDN1 
(endothelin-1), AT1A (angiotensin II receptor isoform A), and SEMA3C (semaphorin 3C) [45]. In 
addition, either GATA-4 or GATA-6 is essential for expression of other cardio-associated TFs that 
regulate the onset of cardiomyocyte gene expression in early cardiogenesis. Not surprisingly, when 
both GATA-4 and GATA-6 were simultaneously disrupted in mouse embryos, the onset of cardiac 
development was completely blocked [46]. 
 
GATA-4 and GATA-6 are expressed in both fetal and adult cardiomyocytes and required for 
physiological hypertrophic remodeling during postnatal heart growth as suggested by controlled 
GATA-4 [47] and GATA-6 overexpression [48, 49] in the heart. There is a good reverse correlation 
between these results and the data from conditional GATA-4-/GATA-6-knockout models: Mutant 
mice with mid-to-late fetal cardio-specific deletion of GATA-4 [50] or combined deletion of 
GATA-4 and GATA-6 [49] develop dilated cardiomyopathy with severe systolic dysfunction in 
adulthood. Similarly, the simultaneous loss of both GATA-4 and GATA-6 in perinatal 
cardiomyocytes causes progressive systolic dysfunction and ventricular dilatation [51]. 
 
GATA-4 and GATA-6 regulate cardiac morphogenesis, cardiomyocyte differentiation, and gene 
expression in a dosage-dependent manner. Mice homozygous for a hypomorphic GATA-4 
mutation (GATA-4
H/H
 mice), expressing 70 % less GATA-4 protein in the atria and LV, displayed 
a common atrioventricular canal, double outlet right ventricle, and hypoplasia of the LV compact 
myocardium. Altered diastolic function was suspected in mutants because ventricular active 
relaxation was found to be correlated with the compact myocardium development in normal 
mouse embryos [52]. In fact, in vivo hemodynamics in GATA-4
H/H
 mice did reveal signs of severe 
diastolic dysfunction, in the absence of changes in systolic function. The diastolic dysfunction 
phenotype of these mutants did not result from downregulation of putative GATA-4 target genes in 
the heart; GATA-6 expression was not altered in GATA-4
H/H
 mutant embryos [53]. This fetal heart 
model was suggestive of a possible involvement of GATA-4 in the regulation of diastolic function 
of fetal heart. However, the possibility of a direct causative role for GATA-4 in regulating the 
diastolic function remained in question, since mutant mice lacking 70 % of the GATA-4 protein 
displayed complex cardiac structural and functional abnormalities. 
 
Recently, the functions of GATA-4 and GATA-6 in adult heart have been highlighted using 
mouse models of temporally controlled, cardiomyocyte-specific gene inactivation [51]. In the 
adult heart, simultaneous cardiomyocyte-specific deletion of GATA-4 and GATA-6 leads to 
dramatically attenuated diastolic function, whereas systolic performance is only slightly impaired. 
Molecular characterization of these mutant mice demonstrated that expression of the GATA-4 
preferential target, MYH6 (myosin, heavy chain 6, cardiac muscle, alpha), is decreased in the 
diastolic heart. However, the expression of the other GATA-4-dependent gene, MYH7 (myosin, 
heavy chain 7, cardiac muscle, beta) as well as the NPPA gene (a bona fide target for both GATA-4 
y GATA-6 factors [54]) is increased in mutant myocardium, suggesting that the diastolic phenotype 
could not result from a general downregulation of GATA-4/6 target genes. 
Overall, therefore, the results of GATA-4 and GATA-6 knockdown in the adult heart strongly 
suggest that stress-induced downregulation of these TFs in myocardium might play a critical role 
in or contribute to the development of diastolic dysfunction. It should be noted in this sense that 
either GATA-4 or GATA-6 physically interact with FOG-2 (friend of GATA-2), a multi-zinc 
finger transcription cofactor, which is co-expressed with GATA-4/6 in the heart and is known to 
potently repress GATA-4 activation of target promoters (reviewed in [55]). Adult mice with fetal 
cardiomyocyte-restricted loss of FOG-2 developed a dilated cardiac phenotype, indicating that 
FOG-2 is required for normal adult heart function [56]. FOG-2 upregulation is a feature of human 
cardiomyopathic heart. Mice with cardiac-specific overexpression of FOG-2 display normal-sized 
ventricles with enlarged atria; a significant downregulation of MYH6 and SERCA2a was found in 
ventricular myocardium of FOG-2 transgenic mice [57]. Although unproven as yet, it is tempting 
to speculate that a severe decrease in GATA-4 and GATA-6 transcriptional activity, which could 
lead to diastolic dysfunction [51], might be associated, at least in part, with overexpression of 
FOG-2 in the stressed heart. 
  
SRF and myocardin transcriptional regulators 
Serum response factor (SRF) is a founding member of the MADS (MCM1, agamous, 
deficiens, and SRF)-box superfamily of TFs. This ubiquitously expressed TF binds DNA as a 
dimer (through the highly conserved DNA-binding and dimerization MADS-box domain) and 
regulates many target genes through serum response elements in their promoters (reviewed in [58, 
59]). More than 200 SRF-dependent genes that are important for metabolism, cytoskeleton, 
extracellular matrix, ion transport, stress response, transcription, and translational regulation have 
been identified in the ventricular myocardium [24, 60]. Alternative splicing generates several 
isoforms of SRF, with full-length SRF being the predominant cardiac isoform. SRF is highly 
expressed in the heart during embryonic, fetal, and postnatal development. Gene-targeting studies 
in mouse models provided insights into potentially pathological consequences of both SRF 
redundancy and deficiency in the adult heart. Augmented SRF expression leads to hypertrophic 
cardiomyopathy, while inhibition of SRF activity results in development of dilated 
cardiomyopathy (reviewed in [61, 62]). 
 
During aging, the heart undergoes, even in the absence of evident cardiovascular pathology, 
subtle remodeling changes that include moderate LV hypertrophy and altered LV diastolic 
function. SRF expression is increased from adulthood to senescence. In this context, in transgenic 
mouse models, in which upregulation of the SRF gene was low-to-mild, young adult animals 
displayed accelerated cardiac aging and developed diastolic dysfunction [63]. A subsequent report 
showed that a low-forced SRF expression did not affect either cardiac gene expression or cellular 
structure [64]. Whether low-amplitude increases in cardiac SRF levels are causative for triggering 
diastolic dysfunction or merely reflective of aging heart remodeling remained unclear. 
 
SRF is characterized by a relatively low intrinsic transcriptional activity itself, but its 
association with a wide array of cofactors that possess potent transactivation domains leads to a 
strong enhancement of SRF transactivation capacity in a cell context-dependent manner. One of 
such cofactors is myocardin (MYOCD) that regulates the expression of multiple smooth muscle 
(SM) and cardiac contractile genes, including CNN1 (calponin 1, basic, smooth muscle), MYH11 
(myosin, heavy chain 11, smooth muscle), ACTA2 (actin, alpha 2, smooth muscle, aorta), ACTG2 
(actin, gamma 2, smooth muscle), TAGLN (transgelin), and MYH6 (myosin, heavy chain 6, cardiac 
muscle, alpha) (reviewed in [23, 65–68]). 
 
Loss- and gain-of-function experiments demonstrated that MYOCD is absolutely required for 
maintenance of adult heart function. Postnatal cardio-restricted MYOCD knockdown induces 
dilated cardiomyopathy and fatal HF in mice [69], while forced expression of MYOCD in 
ventricular myocardium impairs LV systolic function and cardiac ECG activity in pigs [70]. In 
light of these results, it comes as no surprise that a strong association between the altered 
expression of MYOCD and cardiac pathological conditions has been established in different animal 
models as well as patients with end-stage HF (reviewed in [23, 67, 68]). 
 
In the porcine model of doxorubicin (Dox)-induced HFpEF, gene expression profiling revealed 
a significant upregulation of MYOCD- and MYOCD-dependent SM genes in falling LV 
myocardium, with the SRF levels unchanged as compared to controls. ACTG2 was the most 
remarkably upregulated MYOCD target gene in Dox-injected piglets. Of note, the ectopic 
expression of ACTG2 in the mouse heart significantly reduces the rates of ventricular relaxation 
[71]. In vivo silencing of endogenous upregulated MYOCD via intramyocardial delivery of short-
hairpin RNAs at mid-advanced stages of HFpEF resulted in downregulation of MYOCD-
dependent SM gene expression in the failing porcine myocardium. Such adjusting of MYOCD and 
SM-target expression levels to the range of physiological variation led to restoring diastolic 
function and extending the survival of failing animals without compromising the physiological 
functions of MYOCD signaling as part of the adaptive response of the heart to stress [72]. These 
findings demonstrate that the normalization of altered MYOCD signaling could represent a 
strategic operative tool for the prevention of the development of diastolic dysfunction. 
  
NRF2 transcription factor 
Nuclear factor erythroid 2-related factor 2 (NRF2) is a redox-sensitive basic leucine zipper TF 
which controls the gene expression of several hundred of detoxification and antioxidant enzymes 
bearing a target sequence, known as the antioxidant-responsive element (ARE), in their promoters 
[73]. NRF2 transcriptionally activates ARE-bearing genes in response to oxidative stress-induced 
injury (reviewed in [74, 75]). NRF2 ubiquitously expressed in the cardiovascular system is an 
essential endogenous suppressor of oxidative stress in both cardiomyocytes and cardiac 
fibroblasts, and NRF2 deficiency appears to be a condition for the early onset of HF in humans 
[76, 77]. In addition, functional NRF2 polymorphisms are associated with risk of human 
cardiovascular disorders [78]. 
 
The results from loss- and gain-of-function experiments in animal models have provided clues 
to the understanding of the role/impact of NRF2 in cardiac function. Several lines of mice devoid 
of NRF2 have been generated by homologous recombination in embryonic stem cells, using 
various strategies. In all cases, disruption of the targeted NRF2 gene did not lead to any apparent 
structural and functional abnormalities in the neonatal and early postnatal heart under non-stressed 
physiological conditions [79]. However, NRF2 deficiency resulted in a rapid onset of cardiac 
dysfunction during experimental pressure overload (due to transverse aortic constriction [80]) or 
regional ischemic injury (due to cardiac artery occlusion [81, 82] in young adult (2-month-old) 
mice. These results indicated that NRF2 inhibition can increase sensitivity of the young heart to 
pathological stress and thus exaggerate susceptibility to cardiac dysfunction. Recently, it was 
found that NRF2 loss-of-function leads to suppression and distortion of regenerative processes in 
the apex resection mouse model [82]. 
 
Further studies focused on adult NRF2-knockout mice (5–6 months of age) demonstrated that a 
NRF2 gene deficiency leads to the development of LV diastolic dysfunction even in non-stressed 
heart. Impaired diastolic function in these NRF2 knockouts was associated with mild cardiac 
hypertrophy but preserved systolic function. In addition, a significant decline in cardiac SERCA2a 
and total glutathione levels were found in the myocardium of these animals [83]. The results 
suggest that NRF2 is an essential regulator of cardiac diastolic function upon non-stressed 
physiological conditions and that its downregulation might cause severe maladaptive reactions. 
 
NRF2 expression is upregulated during early stages of physiological cardiac hypertrophy but 
decreased at mild pathological hypertrophy (a condition often associated with HFpEF 
development). In various models of hypertrophic cardiomyopathy, forced expression of NRF2 and 
its target genes, such as HO-1 (heme oxygenase-1), GPX (glutathione peroxidise), TXNRD1 
(thioredoxin reductase 1), NQO1 (NADPH:oxioreductase 1), and SOD2 (superoxide dismutase 2, 
mitochondrial), significantly reverses LV remodeling and fibrosis [84, 85]. Similarly, an increase 
in NRF2 expression/activity (due to phytochemical intake) attenuates diastolic dysfunction in 
hypertensive Dahl salt-sensitive rats with HFpEF [86]. 
 
In patients, diabetic cardiomyopathy is characterized by signs of clinically significant diastolic 
dysfunction independent of coronary disease or hypertension [87]. Expression of NRF2 is 
downregulated in cardiomyocyte nuclei in cardiac samples from patients with diabetes. 
Promisingly, emerging evidence revealed that induction of NRF2 expression can protect from 
diabetes-associated cardiac dysfunction by decreasing the oxidative stress and preventing 
oxidative DNA damage of myocardium (reviewed in [88, 89]). 
  
PITX2 transcription factor 
The PITX2, a paired-like homeodomain transcription factor 2, was originally identified as the 
candidate gene for the human Axenfeld-Rieger syndrome [90] associated, although not frequently, 
with congenital heart defects [91, 92]. Aggregating evidence demonstrates that PITX2 is 
expressed, as three distinct variants/isoforms (A, B, and C), in the mammalian and human heart, 
with PITX2C being the predominant or the only variant detected in the adult LV myocardium [93–
98]. A fourth isoform, PITX2D described, to date, only in humans acts as a dominant-negative 
factor [99]. PITX2 regulates the expression of cyclin D2 (CCND2) [100], forkhead box J1 
(FOXJ1) TF [101], lymphoid enhancer factor (LEF-1) [102], natriuretic peptide precursor A 
(NPPA) [103, 104], myogenic factor 5 (MYF5) [105], and antioxidant scavenger genes [82]. Other 
target genes of PITX2 include channel and calcium-handling genes, and genes are expressed in 
intercalated disks of cardiac myocytes (recently reviewed in [106]). 
 
Selective PITX2 deletion in the developing myocardium resulted in delayed differentiation of 
ventricular (but not atrial) cardiomyocytes and enlargement of right heart chambers associated 
with severely impaired ventricular systolic function [107]. The roles played by PITX2 within the 
four chambered adult heart are still poorly understood. Genes involved in cell junction assembly, 
ion transport, and proliferation pathways were found to be activated in mouse mutants with 
conditionally inactivated PITX2 in the postnatal atrial myocardium [108], but it is unclear whether 
these are direct or indirect PIXT2C target genes in a cardiomyocyte background. Recently, a total 
of 505 direct PITX2 target genes were identified in the mouse postnatal ventricular myocardium, 
including genes encoding transport chain components and reactive oxygen species scavengers 
[82]. 
 
While several lines of evidence from animal models as well as clinical studies strongly support 
that PITX2C has a role in susceptibility to atrial fibrillation [94, 109–114], the relevance of this TF 
to LV diastolic dysfunction remained unsuspected and was therefore not tested till recently. LV 
levels of PITX2C mRNA and protein were first shown to be elevated in the Dox-induced porcine 
model of HFpEF [97]. In particular, it was found that the expression of PITX2C is significantly re-
activated in HFpEF myocardium which, in turn, is associated with increased expression of a 
restrictive set of PITX2 target genes. Among these, MYF5 (myogenic factor 5) was identified as 
the top upregulated gene. In vitro, forced expression of PITX2C in cardiomyocytes activates MYF5 
in dose-dependent manner. Of note, ectopic overexpression of MYF5 in the heart activates a 
skeletal muscle gene expression that results in progressive cardiomyopathy [115, 116]. The latter 
suggests that aberrant PITX2–MYF5 co-activation seen in the porcine model of HFpEF might 
negatively impact on diastolic cardiac function. 
 
Expression of both PITX2 and MYF5 was detected in LV myocardium from HFpEF piglets 
[97] as well as cardiomyocyte-like (CML) cells from patients with dilated cardiomyopathy. Forced 
expression of SERCA2a improved contractility of CML cells that, in turn, was associated with 
downregulation of PITX2 and MYF5 in SERCA2a-transduced cardiomyocytes [117]. Myocardial 
hypertrophy and subsequent diastolic dysfunction are prominent features of diabetic 
cardiomyopathy. In this sense, PITX2C is significantly upregulated in human cardiac myocytes in 
response to high glucose treatment [118]. 
 
In spite of the results discussed above, it is not known whether upregulation of PITX2C can 
cause HFpEF or if its activation is merely a secondary manifestation of impaired LV diastolic 
function. Notably, PITX2 expression is induced in ischemically injured ventricular myocardium 
and is required for neonatal cardiac regeneration in mice [82]. 
  
Conclusions and perspectives 
HFpEF can be considered as the new epidemic of the twenty-first century, since the prevalence 
of this complex clinical syndrome caused by a variety of diseases has remained high or has even 
increased throughout the last two decades (reviewed in [6]). Investigation into molecular 
mechanisms underlying HFpEF has been hampered by lack of relevant and tractable models in 
animals which could recapitulate phenotypic features of diastolic dysfunction in humans. 
Nevertheless, some studies which focused on single specific endpoints have revealed concordant 
changes in increased calcium and sodium levels and elevated expression of the stiff titin isoform 
with myocardial diastolic dysfunction (reviewed in [3]). Despite these efforts, advancement has 
been made over the past several years, proving essential for the identification of the transcriptional 
regulation of diastolic function with potential implications for HFpEF. Surprisingly, the study of 
the molecular regulatory background of diastolic dysfunction and HFpEF does not show a great 
diversity of responsible TFs and downstream gene pathways (Fig. 2). All of these TFs play 
important roles in cardiac development and regulate inducible gene expression in cardiac 
myocytes in the adult heart. It should be pointed out that there is an experimental evidence to 
suggest that diastolic dysfunction could result from altered expression of more than one of these 
TFs in the LV myocardium. In the porcine model of HFpEF, upregulation of MYOCD and its SM-
target genes is associated with augmented PITX2 and MYF5 expression, suggesting an additive 




Fig. 2. Dissecting the roles of cardiac TFs in development of diastolic 
dysfunction. Cardiac transcription factors (TFs) are members of gene 
regulatory circuits, each of which can play a role in the control of a 
branch of terminal effector genes in ventricular myocardium. The results 
from loss- and gain-of-function experiments in animal models provide 
clues toward the understanding the roles of TBX5, GATA-4/6, 
SRF/MYOCD, NRF2, and PITX2 in development of cardiac diastolic 
dysfunction. Severe inhibition of TBX5, GATA-4/6, and NRF2 as well as 
augmented expression of SRF/MYOCD and PITX2 leads to molecular 
changes that may contribute to ventricular diastolic impairment. These 
changes include, respectively, downregulation of SERCA2a, MYH6, and 
antioxidative enzyme (AOE) genes, on the one hand, and activation of 
smooth muscle (SM) and skeletal muscle (MYF5) gene expression in 
ventricular myocardium, on the other hand. AOE—NRF2 target genes 
encoding HO-1, GPX, TXNRD1, NQO1 (NAD(P), SOD2, and SOD3. 
SM—MYOCD target genes encoding CNN1, MYH11, ACTA2, 
ACTG2, and TAGLN. See text for further details 
 
  
The discovery that deficiency in core cardiac TFs, such as TBX5, GATA-4/6 and NRF2, causes 
diastolic dysfunction will prompt an evaluation or re-evaluation of the expression of these TFs in 
other animal models of HFpEF as well as patients with diastolic dysfunction. Perhaps, the best 
example of this is the identification of a TBX5-dependent pathway in the regulation of diastolic 
function that has direct relevance to patients with HOS [38]. Collectively, the results suggest that 
mutant mice with cardio-specific knockdown of TBX5, GATA-4/6, or NRF2 are promising models 
for investigating the molecular mechanisms underpinning the development of diastolic 
dysfunction. 
 
Through the use of other animal models that mimic of HFpEF, upregulation of SRF, MYOCD, 
and PITX2 is linked to the development of diastolic dysfunction, whereas restoration of their 
altered expression to the range of physiological variation can potentially reduce or even eliminate 
diseases, as demonstrated through silencing MYOCD overexpression in the porcine model of 
HFpEF [72]. Of note, detection of elevated levels of MYOCD in circulating blood cells has been 
shown to have a certain biomarker utility in patients (reviewed in [68]). Thus, it appears to be 
reasonable to test whether adjusting a given TF expression level to the range of its physiological 
variation may lead to restoring diastolic function in preclinical settings. 
 
In sum, the above studies clearly illustrate how inappropriately high or low expression of a set 
of cardiac TFs can lead to diastolic dysfunction (see Fig. 2). Therefore, manipulating their levels to 
either increase the expression of stress-downregulated TFs or suppress the expression of stress-
upregulated TFs may represent therapeutic tools to ameliorate HFpEF progression. 
Mechanistically viewed, modulation of TFs in myocardium in vivo can be achieved by direct 
targeting (through gene therapy) their expression levels as well as by affecting the combinatory TF 
interactions (see Fig. 1b) or altering their DNA-binding activity (reviewed in [25]). In this context, 
a number of delivery platforms have been described that are translatable to the clinical setting 
(reviewed in [119]). However, it is necessary to develop more efficient delivery systems for 
cardio-selective (not systemic) targeting of TFs in the diastolic heart. An alternative and 
complementary approach (as demonstrated in the case of NRF2; see [89]) may be pharmacological 
activation/inhibition of the candidate TF or its critical cofactors for improving diastolic 
dysfunction in certain cardiovascular settings. 
 
In addition to the points raised above, it is essential to pinpoint a possible involvement of 
microRNAs (miRNAs) in pathophysiological mechanisms underlying HFpEF (recently reviewed 
in [120]). Compared to the cardiac-enriched TFs (cardiac TF-ome system) which control gene 
expression at the level of transcriptional regulation, cardiac-expressed microRNAs (cardiac 
miRNA-ome system) regulate gene expression at posttranscriptional levels. Rather than acting 
independently of one another, these systems act in an integrated fashion to regulate cardiac gene 
expression in a coordinated manner. In fact, several cardiac-expressed miRNAs were found to be 
involved in the TBX5 [114, 121], GATA-4 [122–126], SRF/MYOCD [124, 126, 127], and PITX2 
[97] regulatory network in settings of cardiovascular disease. There is evidence that circulating 
miRNAs may be used as biomarkers for patients with HFpEF, but their expression has not yet 
been assessed in the diastolic heart [128]. Nonetheless, each advance discussed above highlights 
the importance of multiple layers of molecular control in regulating cardiac gene expression at 
HFpEF. 
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